Axa
MACK

Axa’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Axa’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-3,368
Closed -$33K – 1400
2017
Q2 		$33K Sell
3,368
-96,301
-97% -$1.97M ﹤0.01% 1234
2017
Q1 		$2.42M Sell
99,669
-23,264
-19% -$582K 0.01% 744
2016
Q4 		$3.95M Buy
122,933
+2,337
+2% +$99.7K 0.02% 628
2016
Q3 		$6.03M Buy
120,596
+70
+0.1% +$2.91K 0.03% 529
2016
Q2 		$5.11M Buy
120,526
+67,405
+127% +$3.67M 0.02% 562
2016
Q1 		$3.5M Sell
53,121
-858
-2% -$44.8K 0.02% 644
2015
Q4 		$3.35M Sell
53,979
-1,134
-2% -$79.8K 0.01% 665
2015
Q3 		$3.69M Sell
55,113
-1,166
-2% -$95.2K 0.02% 644
2015
Q2 		$5.47M Hold
56,279
– – 0.02% 572
2015
Q1 		$5.26M Buy
56,279
+35,221
+167% +$3M 0.02% 592
2014
Q4 		$1.87M Buy
+21,058
New +$1.53M 0.01% 809

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa's MACK Position: Q3 2017 in Review

Axa sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2017, closing a stake of 3,368 shares — an estimated $33K sold.

Axa first reported a position in MACK in Q4 2014 and held it in 11 quarters. The position peaked at $6.03M in Q3 2016. 73 funds tracked by Wall St. Rank hold MACK as of Q3 2017.

  • Axa reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Axa sold 3,368 Merrimack Pharmaceuticals, Inc. shares in Q3 2017, an estimated $33K.
  • Axa first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 11 quarters.
  • Axa's Merrimack Pharmaceuticals, Inc. position peaked at $6.03M in Q3 2016.
  • 73 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2017.

Based on Axa's 13F filing for Q3 2017, filed 13 Nov 2017.